SI3066091T1 - NMDA antagonist predzdravila - Google Patents

NMDA antagonist predzdravila

Info

Publication number
SI3066091T1
SI3066091T1 SI201431242T SI201431242T SI3066091T1 SI 3066091 T1 SI3066091 T1 SI 3066091T1 SI 201431242 T SI201431242 T SI 201431242T SI 201431242 T SI201431242 T SI 201431242T SI 3066091 T1 SI3066091 T1 SI 3066091T1
Authority
SI
Slovenia
Prior art keywords
nmda
prodrug
antagonist
prodrug antagonist
nmda prodrug
Prior art date
Application number
SI201431242T
Other languages
English (en)
Slovenian (sl)
Inventor
Gunnar Nordvall
Katharina Hogdin
Per Jonas Malmborg
Annika Kers
Dirk Weigelt
Peter Bernstein
Michael Quirk
Michael Balestra
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI3066091T1 publication Critical patent/SI3066091T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201431242T 2013-11-05 2014-10-30 NMDA antagonist predzdravila SI3066091T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899903P 2013-11-05 2013-11-05
EP14802476.3A EP3066091B1 (en) 2013-11-05 2014-10-30 Nmda antagonist prodrugs
PCT/GB2014/053236 WO2015067923A1 (en) 2013-11-05 2014-10-30 Nmda antagonist prodrugs

Publications (1)

Publication Number Publication Date
SI3066091T1 true SI3066091T1 (sl) 2019-09-30

Family

ID=51947383

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431242T SI3066091T1 (sl) 2013-11-05 2014-10-30 NMDA antagonist predzdravila

Country Status (25)

Country Link
US (4) US9822075B2 (enExample)
EP (3) EP3066091B1 (enExample)
JP (4) JP6479834B2 (enExample)
KR (2) KR102336426B1 (enExample)
CN (2) CN111187202B (enExample)
AR (1) AR098319A1 (enExample)
AU (1) AU2014345407B2 (enExample)
CA (1) CA2928004C (enExample)
CY (1) CY1121749T1 (enExample)
DK (1) DK3066091T3 (enExample)
ES (3) ES2733344T3 (enExample)
HR (2) HRP20191159T1 (enExample)
HU (2) HUE070532T2 (enExample)
LT (1) LT3066091T (enExample)
MX (2) MX394633B (enExample)
PL (2) PL4001272T3 (enExample)
PT (1) PT3066091T (enExample)
RS (2) RS58991B1 (enExample)
RU (1) RU2695372C2 (enExample)
SI (1) SI3066091T1 (enExample)
SM (1) SMT202500023T1 (enExample)
TR (1) TR201909632T4 (enExample)
TW (1) TW201609653A (enExample)
UY (1) UY35823A (enExample)
WO (1) WO2015067923A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102336426B1 (ko) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
CN107578281B (zh) * 2017-08-31 2021-03-30 湖南大学 电子商务环境下用户优惠券行为预测方法及模型构建方法
BR112022025900A2 (pt) 2020-06-23 2023-01-10 Biohaven Therapeutics Ltd Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina
CN122421958A (zh) * 2023-12-22 2026-07-17 拜奥海芬治疗学有限公司 神经性障碍的组合治疗

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7909514L (sv) * 1979-11-16 1981-05-17 Astra Laekemedel Ab Nya halofenyl-pyridyl-allylaminderivat
US4769466A (en) 1987-02-06 1988-09-06 Pennwalt Corporation 2-aminoacetamide pyridinyl derivatives
ES2083972T3 (es) * 1988-08-12 1996-05-01 Astra Ab Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras.
ES2142320T3 (es) 1991-10-30 2000-04-16 Astra Ab Derivados de 2-pirazinil-etilamina y su uso como productos farmaceuticos.
NZ251384A (en) * 1992-04-03 1996-10-28 Fisons Corp (s)-enantiomer of 1-phenyl-2-(2-pyridinyl) ethylamine and medicaments
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
PA8525601A1 (es) 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
AU2002310409C1 (en) 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
CA2551859C (en) 2003-12-30 2011-10-04 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
EP1929030A2 (en) * 2005-09-08 2008-06-11 Shire LLC Prodrugs of t3 and t4 with enhanced bioavailability
CN101246417B (zh) 2007-02-13 2010-09-29 艾威梯科技(北京)有限公司 音频数据流输入/输出无间断软件切换的方法和系统
CA2710538A1 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2010017504A1 (en) * 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US9062094B2 (en) * 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US8580850B2 (en) * 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
KR102336426B1 (ko) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물

Also Published As

Publication number Publication date
HUE045001T2 (hu) 2019-12-30
CN105683180B (zh) 2020-01-21
EP4001272B1 (en) 2024-11-13
US20190152914A1 (en) 2019-05-23
EP3066091A1 (en) 2016-09-14
EP4001272C0 (en) 2024-11-13
KR20210148443A (ko) 2021-12-07
CA2928004C (en) 2022-04-12
ES2999064T3 (en) 2025-02-24
CN105683180A (zh) 2016-06-15
HUE070532T2 (hu) 2025-06-28
PT3066091T (pt) 2019-07-11
JP2021100950A (ja) 2021-07-08
HRP20191159T1 (hr) 2019-10-04
JP2016535098A (ja) 2016-11-10
CY1121749T1 (el) 2020-07-31
RU2016119493A3 (enExample) 2018-06-29
US12516023B2 (en) 2026-01-06
AU2014345407A1 (en) 2016-06-02
BR112016009949A8 (pt) 2020-04-14
JP7234278B2 (ja) 2023-03-07
AU2014345407B2 (en) 2018-10-18
US10815199B2 (en) 2020-10-27
SMT202500023T1 (it) 2025-03-12
RS66369B1 (sr) 2025-01-31
AR098319A1 (es) 2016-05-26
KR102336426B1 (ko) 2021-12-08
KR20160079094A (ko) 2016-07-05
RS58991B1 (sr) 2019-08-30
JP6856737B2 (ja) 2021-04-07
MX2020011946A (es) 2022-08-10
MX2016005567A (es) 2016-07-21
JP2019081781A (ja) 2019-05-30
JP6633233B2 (ja) 2020-01-22
US20180037550A1 (en) 2018-02-08
US9822075B2 (en) 2017-11-21
TR201909632T4 (tr) 2019-07-22
US20160280647A1 (en) 2016-09-29
MX377276B (es) 2025-03-07
PL3066091T3 (pl) 2019-10-31
RU2016119493A (ru) 2017-12-07
CN111187202B (zh) 2025-01-21
EP3066091B1 (en) 2019-04-03
ES2894903T3 (es) 2022-02-16
HRP20241784T1 (hr) 2025-02-28
LT3066091T (lt) 2019-07-10
MX394633B (es) 2025-03-24
CN111187202A (zh) 2020-05-22
JP2020055857A (ja) 2020-04-09
JP6479834B2 (ja) 2019-03-06
UY35823A (es) 2015-04-30
EP4001272A1 (en) 2022-05-25
RU2695372C2 (ru) 2019-07-23
US10207994B2 (en) 2019-02-19
TW201609653A (zh) 2016-03-16
US20210040039A1 (en) 2021-02-11
KR102469167B1 (ko) 2022-11-22
CA2928004A1 (en) 2015-05-14
WO2015067923A1 (en) 2015-05-14
DK3066091T3 (da) 2019-07-15
PL4001272T3 (pl) 2025-02-10
ES2733344T3 (es) 2019-11-28
EP3564234B1 (en) 2021-09-29
EP3564234A1 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
FIC20240001I1 (fi) Tislelitsumabi
NO2023037I1 (no) Mirikizumab
LT3060041T (lt) Prostaciklino junginiai
EP3023769A4 (en) SPECTROSCOPE
DK3613453T3 (da) Fordamper
HRP20181334T1 (hr) Samohodno plovilo
DK2970336T3 (da) Tetrahydropyrrolothiazinforbindelser
DE112014002686A5 (de) Messgerät
HUE037097T2 (hu) Hõszigetelõpanel
DK3077047T3 (da) Aramcholsalte
PT3055308T (pt) Resumo
EP2959561A4 (en) SELF-FORMING MICROGRIDS
HUE037417T2 (hu) Szubsztituált imidazopiridazinok
PL2945641T3 (pl) Cykloalkinowe pochodne sacharydów
DE102013106534B8 (de) Chromatographiepipettenspitze
IL240904A0 (en) Azetidinyloxyphenylpyrrolidine compounds
DK3066091T3 (da) Nmda-antagonist-prodrugs
HRP20180618T1 (hr) Spojevi fluorfenilpirazola
HUE050917T2 (hu) Hidrokortizon-tartalmú készítmény
DE112014001252A5 (de) Aufbissschiene
DK2981168T3 (da) Laminitiskile
ITMI20130606A1 (it) Composti naftoeterodiazolici disostituiti
FI10138U1 (fi) Kelkkateltta
FI20165160A7 (fi) Suhteellisen paikan näyttäminen
UA28366S (uk) Підставка для закусок